newly diagnosed type 2 Dm with hba1c of 15 fbs ppbs above 300, stable,

newly diagnosed type 2 Dm with hba1c of 15 fbs ppbs above 300, stable, only complaints of polyuria, creat normal, no proteinuria, no diabetic retinopathy, dylipedemia , Hypothyroidism under treatment... physician has started tresiba 12 units and oha bd containing metformin 500mg sitagliptin 50 mg and glimepride 1mg....is this a correct approach..if not what is the right approach...also tell me what should be the next move of the physician

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

Reading File

Finding Sources

Searching PubMed

type 2 diabetes insulin initiation high HbA1c management guidelines

Finding Sources

Searching PubMed

type 2 diabetes intensive glycemic control basal insulin oral agents

Finding Sources

Searching the Web

ADA 2024 2025 guidelines newly diagnosed type 2 diabetes HbA1c 15 insulin initiation OHA management

Finding Sources

Reading File

Clinical Analysis: Newly Diagnosed T2DM with HbA1c 15%, FBS/PPBS >300 mg/dL

Is the Current Regimen Correct? - Partially, with significant concerns

The Prescribed Regimen:

Tresiba (insulin degludec) 12 units OD
Metformin 500 mg BD
Sitagliptin 50 mg BD
Glimepiride 1 mg BD

What is Right

Basal insulin initiation is appropriate - An HbA1c of 15% and glucose consistently >300 mg/dL represents severe hyperglycemia. The ADA guidelines and Harrison's (22e, 2025) both support starting insulin at diagnosis when HbA1c is significantly elevated (typically >10-11%), alongside OHA. Tresiba (insulin degludec) is a valid choice - an ultra-long-acting basal insulin with low hypoglycemia risk. Starting at 10-12 units is a reasonable initiation dose.
Metformin is correctly included - Metformin is universally endorsed as the backbone of T2DM therapy. Goodman & Gilman's states: "There is consensus that metformin and lifestyle changes should be the first interventions." It also complements basal insulin well.

What is Problematic

1. Glimepiride + Basal Insulin = Redundant and Dangerous

This is the most significant issue with the regimen.

Glimepiride is a sulfonylurea - it works by stimulating endogenous insulin secretion. When added to exogenous basal insulin (Tresiba), the combination creates a significant hypoglycemia risk, particularly nocturnal hypoglycemia.

Current glucose is >300 mg/dL and HbA1c is 15% - as the insulin dose is titrated upward over days/weeks, the concurrent insulin secretagogue effect of glimepiride dramatically increases hypoglycemia risk.
The dose of Tresiba 12 units will need to be titrated (typically by 2 units every 3 days to target fasting glucose 80-130 mg/dL). As glucose falls toward target, glimepiride will compound hypoglycemic risk.
The GRADE study (referenced in both Harrison's and Goodman & Gilman's) found that basal insulin added to metformin achieves better glycemic control than glimepiride - there is no additive logic in combining both with insulin.

Conclusion: Glimepiride should ideally be avoided or stopped once glucose is coming under control with insulin. Starting glimepiride alongside basal insulin from day 1 in a patient with an HbA1c of 15% that will rapidly drop is not ideal.

2. Sitagliptin Dose Issue

Sitagliptin BD (twice daily) is non-standard - sitagliptin is dosed once daily (100 mg OD), not twice daily. The total dose prescribed here is only 100 mg (50 mg x 2 = 100 mg/day), so this is effectively a once-daily 100 mg dose split, which achieves the same total dose - but once daily is the standard.
Sitagliptin + basal insulin is an acceptable combination - DPP-4 inhibitors work by prolonging endogenous GLP-1/GIP, have low hypoglycemia risk, and are approved as add-on to insulin.
However, in the context of existing glimepiride + insulin, sitagliptin's benefit is marginal and the regimen becomes unnecessarily complex (triple combination with insulin).

3. Metformin Dose is Low

Metformin 500 mg BD (1000 mg/day) is below the optimal dose. Standard dosing for therapeutic effect is 1500-2000 mg/day (starting low and uptitrating to minimize GI side effects is appropriate, but the plan to titrate up should be explicit).

4. No GLP-1 RA or SGLT-2 Inhibitor Considered

This patient also has dyslipidemia - though no established ASCVD is mentioned, the combination of dyslipidemia + newly diagnosed T2DM with severe hyperglycemia makes this patient high cardiovascular risk. According to both Harrison's and Goodman & Gilman's, patients at high cardiovascular or renal risk should have a GLP-1 receptor agonist or SGLT-2 inhibitor considered early. These agents also aid weight loss and reduce cardiovascular events independent of glucose control.

What the Right Approach Should Be

For a newly diagnosed T2DM patient with HbA1c 15%, glucose >300, stable, no DKA, no renal failure, no retinopathy:

Drug	Role	Recommendation
Metformin 500 mg OD → titrate to 1000 mg BD	First-line backbone	Keep, titrate up
Tresiba (insulin degludec) 10-12 units OD	Correct basal insulin choice	Keep, titrate every 3 days
Sitagliptin 100 mg OD (not BD)	Acceptable add-on to insulin	Keep, simplify to OD
Glimepiride	Insulin secretagogue - redundant & risky with insulin	Discontinue or defer until insulin is stopped
GLP-1 RA (e.g., semaglutide/liraglutide)	Cardiovascular benefit + weight loss	Consider adding, especially given dyslipidemia
Statin	Dyslipidemia management	Start - high-intensity statin (atorvastatin 40-80 mg)
Thyroid function	Hypothyroidism affects glucose, lipids, weight	Confirm TSH is well-controlled

What Should the Physician's Next Move Be?

Immediate (Days 1-2 weeks)

Titrate Tresiba - increase by 2 units every 3 days targeting fasting glucose 80-130 mg/dL (4.4-7.2 mmol/L). A simple rule-of-thumb titration: if fasting glucose >180, increase by 4 units; 130-180, increase by 2 units; at target, maintain.
Reconsider Glimepiride - either stop it now, or plan a clear exit point. If the physician wants to retain it short-term for PPBS control, the patient must be educated about hypoglycemia symptoms and have a glucometer.
Titrate Metformin up - after 1-2 weeks at 500 mg BD (to minimize GI side effects), increase to 1000 mg BD.
Glucose monitoring - instruct patient on daily fasting glucometry; ideally also check 2-hour post-meal readings twice weekly.
Address dyslipidemia - check fasting lipid profile if not done; start statin therapy. Note: uncontrolled diabetes itself raises triglycerides and LDL; some dyslipidemia will improve with glucose control.
Confirm thyroid status - check TSH; hypothyroidism increases insulin resistance and worsens lipids. Ensure levothyroxine dose is adequate.

At 3-Month Follow-up

Repeat HbA1c - target <7% (or <8% if older/comorbid). With insulin + metformin, expect significant reduction from 15%.
Once HbA1c approaches target (<8%) - consider whether insulin can be weaned or whether OHA-only/combination is sustainable.
If insulin dose is stable and glucose controlled - reassess need for glimepiride; consider switching to a GLP-1 RA or SGLT-2 inhibitor instead.
Screen for complications - repeat urine microalbumin (even if creatinine normal), dilated fundus exam (for retinopathy), foot exam, neuropathy screen.
Lipid panel recheck - assess statin response.

Long-term Direction

As hyperglycemia resolves, the physician should aim to de-intensify insulin if beta-cell function allows, and transition toward a metformin + GLP-1 RA (or SGLT-2i) ± DPP-4i regimen - avoiding sulfonylureas long-term where possible due to hypoglycemia risk and weight gain.

Summary

Aspect	Verdict
Basal insulin (Tresiba)	Appropriate - correct class and dose
Metformin	Appropriate - but needs titration up to 1500-2000 mg/day
Sitagliptin (as BD)	Dose split is non-standard; 100 mg OD is correct
Glimepiride with basal insulin	Problematic - hypoglycemia risk, redundant mechanism
Titration plan for Tresiba	Essential - physician must have a clear protocol
Dyslipidemia treatment	Missing - statin should be started
Thyroid re-assessment	Should be confirmed optimally controlled
GLP-1 RA / SGLT-2i	Not required urgently, but worth considering given dyslipidemia and CV risk

The regimen shows good intent - starting basal insulin for high HbA1c is the right call - but the inclusion of glimepiride alongside insulin is a pharmacological redundancy with safety implications. The priority now is structured Tresiba titration, glimepiride re-evaluation, statin initiation, and close glucose monitoring.

Harrison's Principles of Internal Medicine, 22e (2025), Chapter 416: Diabetes Mellitus Management
Goodman & Gilman's Pharmacological Basis of Therapeutics, Chapter 51: Managing the Progression of Type 2 Diabetes

suppose physcian changes oha to metformin 1gm bd and sitagliptin 100 mg and dapa 10 mg...intensifies tresiba...is she right in doing so...or should she just give metformin basal insulin and bolus dose ...or choosing mixtard without oha would have been better approach...also keep in mind patient is elderly overweight female newly diagnosed of diabetes..not too educated

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

I now have enough to give a thorough, well-reasoned answer. Let me synthesize the full clinical analysis.

Is the Revised Regimen Right? - Yes, largely excellent. Here is the full breakdown.

Revised Regimen:

Metformin 1g BD
Sitagliptin 100 mg OD
Dapagliflozin 10 mg OD
Tresiba (insulin degludec) - intensified

Assessment of Each Drug in This Patient's Context

Patient Profile Reminder

Elderly, overweight female
Newly diagnosed T2DM
HbA1c 15%, glucose >300
Only symptom: polyuria
Normal creatinine, no proteinuria, no retinopathy
Dyslipidemia, hypothyroidism on treatment
Low literacy / education level

1. Metformin 1g BD - Correct

The dose upgrade from 500 mg BD to 1g BD is appropriate. Standard target dose for metformin is 2000 mg/day (1g BD). This is the universal backbone. It reduces hepatic glucose output, has no hypoglycemia risk, and causes modest weight reduction - relevant in this overweight patient. Creatinine is normal so it is safe. Continue this.

2. Sitagliptin 100 mg OD - Correct

Standard dose, once daily - this is exactly how it should be dosed.
DPP-4 inhibitors are weight-neutral, have low hypoglycemia risk, and are safe in the elderly.
As an add-on to basal insulin, sitagliptin reduces postprandial glucose without adding hypoglycemia risk.
A good choice for this patient profile. Keep it.

3. Dapagliflozin 10 mg OD - Excellent Addition

This is arguably the most important upgrade the physician made. Here is why:

For this patient specifically:

Weight loss - SGLT-2 inhibitors cause 2-4 kg weight loss over 6-12 months via glycosuria. An overweight patient benefits directly.
Blood pressure reduction - SGLT-2 inhibitors cause mild natriuresis and osmotic diuresis, lowering BP by ~3-5 mmHg systolic. Beneficial in elderly overweight females who are often hypertensive.
Cardiovascular and renal protection - Goldman-Cecil Medicine states: "SGLT-2 inhibitors (e.g., dapagliflozin 10 mg daily) reduce the risk of heart failure hospitalization in patients with type 2 diabetes and cardiovascular risk factors." This patient has dyslipidemia, which elevates her CV risk.
Works independent of insulin - mechanism is purely renal glucose excretion, so it complements both insulin and metformin without duplicating mechanism.
Low hypoglycemia risk - does not stimulate insulin; glucose-lowering effect is self-limiting.

One caution in this patient:

She is elderly and her initial complaint is polyuria. Dapagliflozin causes glycosuria and increased urination. In the short term (first 2-4 weeks while glucose is still very high), it may worsen polyuria temporarily. As glucose normalizes, this resolves.
UTI / genital fungal infection risk - she is an elderly female, already at higher UTI risk. Counsel her specifically on genital hygiene, adequate hydration, and to report burning micturition immediately.
Euglycemic DKA - rare with SGLT-2i in T2DM but worth noting; avoid dapagliflozin if she is fasting for a procedure or becomes unwell with vomiting.
Confirm eGFR is adequate (eGFR >45 mL/min is required per Textbook of Family Medicine).

4. Intensified Tresiba - Correct

Titrating basal insulin upward is the right move. The titration protocol should be structured and simple for a low-literacy patient:

Fasting glucose (mg/dL)	Dose adjustment
>180	Increase by 4 units
140-180	Increase by 2 units
100-140	Increase by 1 unit
80-100	Maintain
<80	Reduce by 2 units

Check fasting glucose every 3 days and adjust accordingly. Target fasting glucose: 80-130 mg/dL.

The Three Regimen Options Compared

Option A: Current Revised Regimen (Metformin + Sitagliptin + Dapagliflozin + Tresiba)

Verdict: Best choice for this patient

Pros	Cons
Evidence-based, guideline-endorsed for high HbA1c	4 drugs - requires counseling on each
Covers fasting glucose (Tresiba) + postprandial (DPP4i + SGLT2i)	Dapagliflozin may worsen polyuria initially
SGLT2i adds weight loss, CV protection, BP lowering	UTI risk in elderly female
Only ONE injection daily - simpler for elderly patient	Tresiba titration requires some patient monitoring
Low hypoglycemia risk (no sulfonylurea)	Cost of newer agents

Option B: Metformin + Basal Insulin + Bolus Insulin (Basal-Bolus Regimen)

Verdict: Physiologically ideal but NOT suitable for this patient

Basal-bolus mimics physiologic insulin secretion most closely (long-acting covers fasting glucose, rapid-acting covers each meal). However, the Textbook of Family Medicine explicitly lists as a key pre-requisite for basal-bolus: "patients' ability to carry out diabetes self-management tasks... learning skill deficiencies including reading, writing, and math/numeracy skills."

This patient is elderly, not well-educated, and newly diagnosed. Basal-bolus means:

4-5 injections per day
Counting carbohydrates at each meal
Calculating variable bolus doses
Frequent blood glucose monitoring
High cognitive and manual dexterity burden

Risk: If she cannot reliably calculate meal-time doses or skips a meal but has already injected bolus insulin, she will have severe hypoglycemia. This is dangerous in the elderly (falls, cardiac arrhythmias, cognitive impairment).

Conclusion: Basal-bolus is NOT the right first choice here - save it for younger, more educated patients or when simpler regimens fail.

Option C: Mixtard (Premixed 30/70 Insulin) Without OHA

Verdict: Simple, but has significant disadvantages - not preferred

Mixtard (biphasic insulin aspart 30% short-acting + 70% intermediate-acting, or NPH combinations) given twice daily (before breakfast and before dinner) is a time-honoured approach for resource-limited or low-literacy settings.

Why it is appealing here:

Simple: just 2 injections/day at fixed times
No OHA complexity
Covers both fasting and postprandial glucose (roughly)
Cheap and widely available

Why it is inferior for this patient:

Problem	Reason
Inflexible	Patient must eat at fixed times and fixed carbohydrate amounts - if she eats late or skips a meal, hypoglycemia is almost certain
Difficult to fine-tune	You cannot adjust basal and prandial components independently
Hypoglycemia-prone	The NPH/70% component peaks in the afternoon and overnight, causing nocturnal hypoglycemia - especially dangerous in the elderly
No CV/renal protection	No SGLT-2 or GLP-1 benefit
Weight gain	Premixed insulin promotes weight gain - not ideal in an overweight patient
Abandoned by guidelines	Modern ADA/EASD guidelines no longer recommend premixed insulin as a standard first approach; basal insulin + OHA is preferred over premixed

Mixtard might still be chosen if:

The patient has no access to/cannot afford modern agents
Healthcare setting is very resource-limited
Stable regular meal patterns can be ensured
Close follow-up is unavailable

What Should the Physician Do Next?

Immediate Priorities (Week 1-2)

Structured Tresiba titration - Give patient a simple written titration guide (or teach a family member). Review fasting glucometry at every visit. Typical final dose for an overweight T2DM patient may reach 30-50 units.
Patient education - SIMPLIFIED - Because she is not highly educated, use pictorial aids:
- Show what hypoglycemia feels like (sweating, trembling, palpitations)
- What to do: drink juice / eat 3-4 glucose tablets immediately
- Never skip a meal after insulin injection
- Keep glucometer and test strips accessible
Counsel specifically on dapagliflozin:
- Polyuria will temporarily increase then reduce as glucose falls
- Maintain adequate hydration
- Wash genital area after urination, report any burning or discharge immediately
- Stop dapagliflozin if vomiting/unable to eat and report to doctor
Initiate statin for dyslipidemia:
- Atorvastatin 20-40 mg OD (titrate to 80 mg if LDL-C target not met)
- Note: untreated dyslipidemia + T2DM = high ASCVD risk even without prior events
Confirm thyroid control:
- Check TSH - uncontrolled hypothyroidism increases insulin resistance, worsens dyslipidemia, and causes weight gain
- Ensure TSH is within 1-2.5 mIU/L
Blood pressure check:
- Elderly overweight T2DM with dyslipidemia - if BP >130/80, start ACE inhibitor or ARB (also has renal-protective benefits)

At 3-Month Follow-up

Repeat HbA1c - expect significant drop from 15% with this regimen; target eventual <7.5% (slightly less strict for elderly to avoid hypoglycemia)
Urine microalbumin - even with normal creatinine, early nephropathy screening
Lipid profile - assess statin response
Dilated fundus exam - comprehensive eye exam even if no visible retinopathy now
Foot exam - peripheral neuropathy/vascular assessment
Reassess insulin dose and OHA as glucose normalizes - once HbA1c approaches 7-8%, consider whether insulin can be weaned

Longer-Term

Once glucose is well-controlled and HbA1c is at target, the physician may attempt a careful insulin wean over months, continuing metformin + dapagliflozin + sitagliptin.
If partial insulin wean is successful (beta-cell function recovering with glucose toxicity resolved), this regimen may sustain good control without insulin.
Consider switching sitagliptin to a GLP-1 receptor agonist (e.g., weekly semaglutide 0.5-1 mg SC) when affordable - superior weight loss, better CV outcomes, and more powerful HbA1c reduction than DPP-4i.

Final Verdict Table

Regimen	Suitability for This Patient
Metformin + Sitagliptin + Dapagliflozin + Tresiba (revised)	Best - evidence-based, CV-protective, weight-friendly, single injection
Metformin + Basal-Bolus Insulin	Not appropriate - too complex, high hypoglycemia risk for elderly, low-literacy patient
Mixtard (premixed) without OHA	Simple but inferior - rigid, hypoglycemia-prone, no CV/metabolic benefit, no longer preferred by modern guidelines

The physician's revised regimen is sound. The key execution priorities are now: structured Tresiba titration, patient education on hypoglycemia and SGLT-2i care, statin initiation, thyroid optimization, and a 3-month review with HbA1c target reassessment.

Goodman & Gilman's Pharmacological Basis of Therapeutics, Ch. 51: Managing the Progression of T2DM
Harrison's Principles of Internal Medicine 22e (2025), Ch. 416: Diabetes Mellitus
Textbook of Family Medicine 9e, Ch. 34: Insulin Initiation for T2DM; Factors for Physiological Insulin Replacement Therapy

This is a shared conversation. Sign in to Orris to start your own chat.